M3 Receptor Internalization Redistribution Assay



The Muscarinic acetylcholine receptor 3 (M3) Redistribution Assay monitors the cellular translocation of GFP-tagged M3 in response to drug compounds or other stimuli and allows easy acquisition of multiple readouts from the same cell in a single assay run.


   Product Detail


M3 Redistribution Assay Features
  • Designed to assay compounds for their ability to modulate Muscarinic acetylcholine receptor 3 (M3) internalization
  • Coupled to EGFP for easy monitoring of the cellular translocation event
  • Robust cell-based assay for use in high content analysis and fluorescence microscope applications

M3 Redistribution Assay Highlights
  • Biologically relevant data: Compounds tested in a cellular environment
  • Validated: Functionally tested cells provided with an optimized assay protocol
  • Easy to use: Just plate cells, add compounds, and image

Muscarinic acetylcholine receptors mediate their effect by exerting metabotropic actions of acetylcholine in the nervous system. The receptors belong to the G-protein-coupled receptor (GPCR) superfamily that transduces signals through multiple intracellular signaling cascades to regulate a wide variety of physiological responses. At present, five receptor subtypes have been identified, where the odd-numbered receptors (M1, M3, M5) preferentially couple to Gαq/11 and activate phospholipase C, thereby initiating the phosphatidylinositol trisphosphate (PIP3) cascade leading to intracellular Ca2+ mobilization and activation of protein kinase C. The even-numbered receptors M2 and M4 couple to Gαi/o and inhibit adenylyl cyclase activity.

Drugs targeting muscarinic acetylcholine receptors are currently used in the treatment of chronic obstructive pulmonary disorder and overactive bladder, but these receptors also represent potential therapeutic targets for cognitive disorders such as Alzheimer’s disease and schizophrenia. Selective M1 agonists or mixed M1 agonists/M2 antagonists may provide an approach to the treatment of cognitive disorders, while M3 antagonism or mixed M2/M3 antagonists are approved for the treatment of contractility disorders including overactive bladder and chronic obstructive pulmonary disease.

Muscarinic acetylcholine receptor 3 (M3) Redistribution Assay Figure 1

Figure 1. Internalization of M3-EGFP stimulated with carbachol. Cells were treated with 300 μM carbachol for 1 hr (right panel) or untreated (DMSO control, left panel). Arrows indicate the M3-EGFP internalization that is detected by the image analysis algorithm.

Muscarinic acetylcholine receptor 3 (M3) Redistribution Assay Figure 2

Figure 2. Carbachol concentration response in the M3 assay. Concentration response was measured in 8 point half log dilution series (n=16). The EC50 of carbachol is ~40 μM. Cells were incubated with carbachol for 1 hr. Cells were then fixed and internalization was measured using the Cellomics ArrayScan VTI Reader and the SpotDetectorV3 BioApplication. % activity was calculated relative to the positive (300 μM carbachol) and negative control (0.25% DMSO).

 M3 Receptor Internalization Redistribution Assay
 Product# Price  Product Name  Cell Line  
         
 076_01 Profiling      -    M3 Redistribution Assay U2OS   SELECT  
 076_01 Screening      -    M3 Redistribution Assay U2OS   SELECT  
Purchase Details
Request Quote
Product Contact
 Sales Contact
  Service Contact